BioLineRx
As of the edition of 20 October 2026, BioLineRx runs 6 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 2 |
| Stopped | 2 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Motixafortide | none listed | 1 |
| Motixafortide acetate | Ends 2030 (exclusivity) | 1 |
A route B row is one company at one target.
Where its trials are
- Blood and lymph: 4 trials led
- Mental health: 4 trials led
- Cancer: 3 trials led